All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How close are we to offering treatment tailored to mutational profile?
Bookmark this article
During the European School of Haematology (ESH) 2nd How to Diagnose and Treat: Acute Leukaemia meeting, the AML Hub spoke to Jorge Sierra, Hospital de la Santa Creu i Sant Pau, Barcelona, ES. In this podcast, Jorge Sierra talks about how close we are to offering treatment tailored to mutational profile.
How close are we to offering treatment tailored to mutational profile?
Jorge Sierra describes the clinical benefit of adding drugs that target mutations into treatment regimens and explains the importance of mutational profiling at diagnosis and relapse to determine treatment options. He discusses target therapies that are available to patients, including
- midostaurin (FLT3 inhibitor) for the frontline setting
- ivosidenib (IDH1 inhibitor) for the relapsed/refractory (R/R) setting
- enasidenib (IDH2 inhibitor) for the R/R setting
- gilteritinib (FLT3 inhibitor) for the R/R setting
He concludes by discussing other novel agents that have shown efficacy in the treatment of AML, including venetoclax and gemtuzumab ozogamicin.
Your opinion matters
3 votes - 1 day left ...
Newsletter
Subscribe to get the best content related to AML delivered to your inbox